Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eastwood Bio-Medical CanadaTSXV:EBM +4.32%25 PS Ratio is 173.64 as of Aug. 27, 2026, which is 153% above its 10-year median of 68.71. GuruFocus rates TSXV:EBM with a GF Score™ of 25/100 and a GF Value™ of C$0.52 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 933 Biotechnology companies, Eastwood Bio-Medical Canada ranks worse than 88.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Eastwood Bio-Medical Canada's share price is C$1.91.
Eastwood Bio-Medical Canada's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was C$0.01. Hence, Eastwood Bio-Medical Canada's PS Ratio for today is 173.64.
Warning Sign:
Eastwood Bio-Medical Canada Inc stock PS Ratio (=175.45) is close to 5-year high of 175.45.
The historical rank and industry rank for Eastwood Bio-Medical Canada's PS Ratio or its related term are showing as below:
TSXV:EBM'
s PS Ratio Range Over the Past 10 Years
Min: 10.71 Med: 68.71 Max: 1696
Current: 175.45
During the past 13 years, Eastwood Bio-Medical Canada's highest PS Ratio was 1696.00. The lowest was 10.71. And the median was 68.71.
TSXV:EBM's PS Ratio is ranked worse than 88.85% of 933
companies
in the Biotechnology industry
Industry Median: 9.6
vs TSXV:EBM: 175.45
Eastwood Bio-Medical Canada Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Eastwood Bio-Medical Canada was 10.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -16.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -2.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 1.50% per year.
During the past 13 years, Eastwood Bio-Medical Canada's highest 3-Year average Revenue per Share Growth Rate was 39.50% per year. The lowest was -16.70% per year. And the median was -4.00% per year.
Eastwood Bio-Medical Canada (TSXV:EBM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Eastwood Bio-Medical Canada PS Ratio Related Terms
Eastwood Bio-Medical Canada PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eastwood Bio-Medical Canada's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eastwood Bio-Medical Canada PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eastwood Bio-Medical Canada's PS Ratio distribution charts can be found below:
* The bar in red indicates where Eastwood Bio-Medical Canada's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Eastwood Bio-Medical Canada's Share Price of today is C$1.91. Eastwood Bio-Medical Canada's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Eastwood Bio-Medical Canada (TSXV:EBM) has a PS Ratio of 173.64 as of Aug. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eastwood Bio-Medical Canada and its competitors. This is 153% above median its historical median of 68.71. Over the past decade, Eastwood Bio-Medical Canada's PS Ratio has ranged from 10.71 to 1,696.00. According to the industry distribution chart, Eastwood Bio-Medical Canada ranks #829 out of 933 companies in the Biotechnology industry, placing it in the top 88.9%.
Is Eastwood Bio-Medical Canada's PS Ratio too high?
Eastwood Bio-Medical Canada's current PS Ratio of 173.64 is 153% above median its 10-year median of 68.71. Over the past 10 years, this metric has ranged from a low of 10.71 to a high of 1,696.00. The Biotechnology industry median PS Ratio is 9.60. Eastwood Bio-Medical Canada's value of 173.64 is 1708.8% above this industry median. Based on the distribution chart, Eastwood Bio-Medical Canada ranks #829 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eastwood Bio-Medical Canada ranks #829 out of 933 companies for PS Ratio. This places Eastwood Bio-Medical Canada in the lower half of its industry. The industry median PS Ratio is 9.60. Eastwood Bio-Medical Canada's value of 173.64 is 1708.8% above this benchmark. Historically, Eastwood Bio-Medical Canada's own PS Ratio has ranged from 10.71 to 1,696.00 over the past decade. While the company's 10-year median is 68.71 vs. the industry median of 9.60, Eastwood Bio-Medical Canada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.60, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eastwood Bio-Medical Canada's current PS Ratio of 173.64 is 1708.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eastwood Bio-Medical Canada and its competitors. For the Biotechnology industry, the median PS Ratio is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eastwood Bio-Medical Canada's current PS Ratio is 173.64, which is 153% above median its own 10-year median of 68.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.52, compared to a current price of C$1.91 — trading 267.3% above its estimated fair value. The current PS Ratio is 173.64, which is 153% above median its 10-year median of 68.71 and 1708.8% above the Biotechnology industry median of 9.60. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current PS Ratio is 173.64 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued.
The current stock price of C$1.91 is trading 267.3% above its estimated GF Value™ of C$0.52.
GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.
Key valuation signals for TSXV:EBM:
PS Ratio: 173.64 (153% above median its 10-year median of 68.71)
GF Value™: C$0.52 vs. price of C$1.91 (267.3% above fair value)
Industry Position: 1708.8% above the Biotechnology median (#829 of 933)
No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score
Get the complete analysis for TSXV:EBM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:EBM has been successfully added to your 
